MedPath

Tagged News

MiraDx and UCLA to Present Groundbreaking Research on MicroRNA-Based Predictive Biomarkers at ASCO 2025

Oncology
  • MiraDx's mirSNP platform demonstrates potential to predict treatment-related toxicity and response in cancer patients, with findings to be presented at ASCO 2025 in collaboration with UCLA researchers.
  • Research on soft tissue sarcoma reveals genetic signatures that can predict major wound toxicity, late toxicity, distant metastases, and pathological response to radiation therapy, potentially enabling more personalized treatment approaches.
  • A second study identifies microRNA-based signatures that predict early and late immune-related adverse events in patients receiving anti-PD1 immunotherapy, addressing a critical challenge in cancer care.

Zepzelca-Tecentriq Combination Shows Survival Benefit in Metastatic Small Cell Lung Cancer

Oncology
  • Phase 3 trial results reveal that combining Zepzelca with Tecentriq as maintenance therapy extended median progression-free survival to 5.4 months versus 2.1 months with Tecentriq alone in metastatic small cell lung cancer patients.
  • The combination therapy demonstrated a significant overall survival advantage, with patients living a median of 13.2 months compared to 10.6 months in the Tecentriq monotherapy group, though with increased side effects.
  • ASCO's Chief Medical Officer described the findings as "a small next step" in treating this aggressive cancer type, suggesting the combination could move into first-line maintenance setting pending regulatory review.

Boehringer Ingelheim Reports Promising Results for SIRP Inhibitors in Cancer Immunotherapy Trials

Monoclonal AntibodyOncology
  • Boehringer Ingelheim's SIRP inhibitor BI 765063, when combined with PD-1 inhibitor ezabenlimab and cetuximab, showed manageable safety and promising antitumor activity in patients with recurrent/metastatic head and neck cancer.
  • The company's next-generation SIRP inhibitor, BI 770371, demonstrated good tolerability both alone and in combination with ezabenlimab in patients with advanced solid tumors, with no dose-limiting toxicities observed.
  • Both antibodies work by blocking the "don't eat me" signal cancer cells use to evade immune detection, potentially enabling immune cells like macrophages to better recognize and destroy tumor cells.

Volastra's Novel KIF18A Inhibitor Shows Promising Results in Ovarian Cancer Patients

Oncology
  • Volastra Therapeutics' oral KIF18A inhibitor VLS-1488 demonstrated tumor reduction in 7 of 17 heavily pre-treated advanced ovarian cancer patients in a Phase I/II trial, with preliminary data to be presented at the 2025 ASCO Annual Meeting.
  • The drug showed a highly favorable safety profile across all tested dose levels (50-800 mg), with no dose-limiting toxicities observed and less than 45% of patients experiencing treatment-related adverse events of any grade.
  • This breakthrough represents a significant milestone in targeting chromosomal instability, a common feature in high-grade serous ovarian cancer, which accounts for approximately 75% of all ovarian cancers and 80% of ovarian cancer deaths.

A Study of Sovilnesib in Subjects With Ovarian Cancer

NCT06084416RecruitingPhase 1
Volastra Therapeutics, Inc.
Posted 4/4/2024

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

NCT05902988RecruitingPhase 1
Volastra Therapeutics, Inc.
Posted 10/18/2023

Linvoseltamab Combination Therapy Shows 90% Response Rate in Relapsed/Refractory Multiple Myeloma

Oncology
  • Regeneron's linvoseltamab, when combined with carfilzomib, demonstrated a 90% objective response rate and 76% complete response rate in relapsed/refractory multiple myeloma patients, with 83% remaining progression-free at 12 months.
  • A second combination with bortezomib showed similarly impressive results with an 85% objective response rate and 50% complete response rate, despite more than half of patients being refractory to proteasome inhibitors.
  • The promising data from the Phase 1b LINKER-MM2 trial will be presented at the upcoming ASCO 2025 Annual Meeting, with a registrational Phase 3 trial for the carfilzomib combination already planned.

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

NCT04722146Active, Not RecruitingPhase 1
Janssen Research & Development, LLC
Posted 3/12/2021

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

NCT05090566Active, Not RecruitingPhase 2
Pfizer
Posted 10/27/2021

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

NCT05052970Unknown StatusPhase 1
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Posted 10/20/2021

GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

NCT05695508RecruitingPhase 2
University of Heidelberg Medical Center
Posted 12/1/2022

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

NCT05137054RecruitingPhase 1
Regeneron Pharmaceuticals
Posted 8/17/2022

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

NCT05652335RecruitingPhase 1
Janssen Research & Development, LLC
Posted 11/22/2022

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

NCT03761108RecruitingPhase 1
Regeneron Pharmaceuticals
Posted 1/23/2019

Amtagvi Shows Unprecedented 20% Five-Year Survival Rate in Advanced Melanoma Patients

Drug ApprovalOncology
  • Iovance Biotherapeutics has announced five-year results from the Phase 2 C-144-01 trial showing that one-time treatment with Amtagvi (lifileucel) achieved a 20% survival rate in advanced melanoma patients previously treated with checkpoint inhibitors.
  • The tumor infiltrating lymphocyte (TIL) therapy demonstrated durable responses with a 31.4% objective response rate and a median duration of response of 36.5 months, with nearly one-third of responders maintaining their responses at the five-year mark.
  • Amtagvi, which received FDA accelerated approval in February 2024, represents a significant breakthrough as the first one-time T cell therapy approved for a solid tumor cancer, offering a new option for patients with limited treatment alternatives.

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

NCT02360579CompletedPhase 2
Iovance Biotherapeutics, Inc.
Posted 9/24/2015

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

NCT05727904RecruitingPhase 3
Iovance Biotherapeutics, Inc.
Posted 3/30/2023

Merus Reports Promising Survival Data for Petosemtamab-Keytruda Combination in Metastatic Head and Neck Cancer

Oncology
  • Merus announced that 79% of patients with newly diagnosed metastatic head and neck cancer survived at least one year when treated with petosemtamab in combination with Keytruda.
  • The preliminary survival data from the mid-stage clinical trial has been well-received by investors, though larger randomized studies will be needed to definitively prove efficacy.
  • Complete results from the Phase 2 trial will be presented at the upcoming American Society of Clinical Oncology (ASCO) annual meeting.

RWJBarnabas Health and Rutgers Cancer Institute to Present 45 Groundbreaking Studies at ASCO 2025

OncologyPrecision MedicineMonoclonal Antibody
• Researchers from RWJBarnabas Health and Rutgers Cancer Institute will showcase 45 innovative cancer studies at the 2025 ASCO Annual Meeting, highlighting advances across multiple tumor types and treatment approaches.
• A notable multisite randomized trial demonstrated that problem-solving skills training significantly improved depression, anxiety, and quality of life in young adults newly diagnosed with cancer compared to standard care.
• New research revealed that patients living in both food and clinical trial deserts had 27% lower likelihood of breast cancer trial enrollment, highlighting how geographic and socioeconomic barriers impact cancer care access.

City of Hope to Present Groundbreaking Cancer Advances at 2025 ASCO Annual Meeting

Precision MedicineOncology
  • City of Hope researchers will showcase innovative cancer treatments at the 2025 ASCO Annual Meeting, including promising data on safely readministering trastuzumab-deruxtecan to breast cancer patients after lung complications.
  • A precision medicine study identified specific genomic biomarkers in kidney cancer patients that predict better outcomes with adjuvant atezolizumab, potentially enabling more personalized treatment approaches.
  • Novel combination therapy using checkpoint inhibitors Vilastobart and atezolizumab showed tumor shrinkage in colorectal cancer patients previously unresponsive to immunotherapy, representing a significant breakthrough.

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382286Active, Not RecruitingPhase 3
Gilead Sciences
Posted 7/25/2022

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

NCT02224781Active, Not RecruitingPhase 3
National Cancer Institute (NCI)
Posted 9/8/2015

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

NCT04607421Active, Not RecruitingPhase 3
Pfizer
Posted 12/21/2020

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

NCT05091567Active, Not RecruitingPhase 3
Hoffmann-La Roche
Posted 11/18/2021

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy

NCT03024996TerminatedPhase 3
Hoffmann-La Roche
Posted 1/3/2017

MInimal Residual Disease Adapted Strategy

NCT04934475Active, Not RecruitingPhase 3
Intergroupe Francophone du Myelome
Posted 12/8/2021

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

NCT04351555Active, Not RecruitingPhase 3
AstraZeneca
Posted 12/16/2020

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

NCT05257408Active, Not RecruitingPhase 3
Corcept Therapeutics
Posted 6/29/2022

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

NCT05740566Active, Not RecruitingPhase 3
Amgen
Posted 5/31/2023

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

NCT03682536Active, Not RecruitingPhase 3
Celgene
Posted 1/2/2019

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934Active, Not RecruitingPhase 3
AstraZeneca
Posted 6/30/2021

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

NCT02998528CompletedPhase 3
Bristol-Myers Squibb
Posted 3/4/2017

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

NCT03969004Active, Not RecruitingPhase 3
Regeneron Pharmaceuticals
Posted 6/4/2019

Trial on Radical Upfront Surgery in Advanced Ovarian Cancer

NCT02828618Active, Not RecruitingNot Applicable
AGO Study Group
Posted 7/1/2016

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

NCT04497844Active, Not RecruitingPhase 3
Janssen Research & Development, LLC
Posted 9/23/2020

Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

NCT04896697RecruitingPhase 1
Xilio Development, Inc.
Posted 9/13/2021

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

NCT03732677Active, Not RecruitingPhase 3
AstraZeneca
Posted 11/16/2018

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

NCT03793166Active, Not RecruitingPhase 3
National Cancer Institute (NCI)
Posted 6/7/2019

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

NCT03336333Active, Not RecruitingPhase 3
BeiGene
Posted 10/31/2017

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

NCT04592913Active, Not RecruitingPhase 3
AstraZeneca
Posted 11/17/2020

Cizzle Bio's CIZ1B Blood Test Could Save Medicare $518 Million Annually in Lung Cancer Screening

Oncology
  • New ASCO study reveals Cizzle Bio's CIZ1B biomarker blood test for early-stage lung cancer detection could save the U.S. Medicare program up to $518 million annually while improving screening accessibility.
  • The CIZ1B test demonstrates 95% sensitivity for Stage I lung cancer detection with a 96% Negative Predictive Value, potentially reducing unnecessary biopsies and increasing early detection rates.
  • Economic models project a 15% increase in screening participation among high-risk Medicare beneficiaries by eliminating barriers associated with traditional low-dose CT screening methods.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.